NCT01547299 2018-10-23
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Pfizer
Phase 2 Completed
Clinical Trials
7 trialsNCT00883909 2017-07-11
ARI103094-Follow-Up Study for REDUCE Study Subjects
GlaxoSmithKline
Completed
NCT01337258 2017-05-30
Economic Analyses of the REDUCE Trial
GlaxoSmithKline
Completed
NCT00470834 2017-02-27
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
GlaxoSmithKline
Phase 4 Completed
NCT00375765 2017-01-19
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
GlaxoSmithKline
Phase 4 Completed
NCT00056407 2016-09-23
REDUCE
GlaxoSmithKline
Phase 3 Completed
NCT00558363 2012-03-21
ARTS
GlaxoSmithKline
Phase 2 Completed